Myomo, Inc. (MYO) Reports Q3 Loss, Beats Revenue Estimates
Myomo, Inc. (MYO) reported a Q3 loss of $0.07 per share, beating estimates of $0.08. Revenue was $12.33M, exceeding expectations by 9.12%. The company has beat EPS and revenue estimates for four consecutive quarters. Shares have risen 33% YTD. Future performance depends on earnings outlook and management commentary.
How this was made
The 30-second read
Why it matters
The earnings beat could trigger short‑term buying, but the overall negative earnings and modest guidance temper expectations.
Market read
Micro‑cap earnings beat with modest upside potential; relevant for traders focused on small‑cap medical device stocks.
What to watch
Future revenue guidance is modest and the company’s cash runway is uncertain, which may limit upside.
Background
Myomo is a medical‑device company listed on NASDAQ. The article provides its Q3 earnings release with surprise metrics.
Ticker impact
Myomo reported Q3 loss of $0.07 per share beating the $0.08 consensus and revenue of $12.33 M beating the $11.28 M estimate.
likely modest upside as market prices in the earnings beat
The surprise on both EPS and revenue suggests short‑term buying pressure, but the company remains small and guidance is still negative.
Market effects
The beat may provide a small lift to the Zacks Medical‑Products sector, but impact is limited.
U.S. small‑cap biotech/medical device space may see slight buying interest.
Limited to investors tracking micro‑cap earnings.
Counterpoint
Despite the beat, the company still posted a loss and guidance remains weak; the stock could face pressure if investors focus on the negative outlook.
Key entities
- CompanyMyomo, Inc.
Medical‑device firm reporting Q3 results.
